sotalol (betapace) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2-adrenergic receptors within bronchial and vascular smooth muscle. It is FDA approved for the treatment of ventricular arrhythmias, symptomatic atrial fibtillation, symptomatic atriall flutter. Common adverse reactions include bradyarrhythmia, chest pain, lightheadedness, palpitations, rash, nausea, dizziness, headache, dyspnea, fatigue. Proarrhythmic events were more common in sotalol treated patients also receiving digoxin. Sotalol should be administered with caution in conjunction with calcium blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. Patients treated with sotalol plus a catecholamine depletor should therefore be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope.   NCATS

Chemistry

  • SMILES: CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
  • InChIKey: ZBMZVLHSJCTVON-UHFFFAOYSA-N
  • Mol. Mass: 272.37
  • ALogP: 1.09
  • ChEMBL Molecules:
    sotalol  
    sotalol hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.0439 - $0.1452

United States

$0.0550 - $1434.8900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide | beta-cardone | betapace | betapace af | dl-sotalol | mj-1999 | sorine | sotacor | sotalex | sotalol | sotalol hcl | sotalol hydrochloride | sotalolo | sotalolum | sotylize

Organizations (70)

Research & Development (53)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (6)


 

Angina Pectoris

Arrhythmias, Cardiac

Atrial Fibrillation (approved 1992)

Atrial Flutter (approved 1992)

Hypertension

Tachycardia, Ventricular (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Ablation Techniques (Phase 2)

Arrhythmias, Cardiac (Phase 4)

Atrial Fibrillation (Phase 4)

Cardiovascular Diseases (Phase 3)

Catheter Ablation (Phase 3)

Coronary Artery Disease (Phase 3)

Death, Sudden (Phase 3)

Death, Sudden, Cardiac (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Fetal Development (Phase 3)

Healthy Volunteers (Phase 1)

Heart Arrest (Phase 3)

Heart Diseases (Phase 3)

Myocardial Infarction (Phase 3)

Stroke (Phase 3)

Tachycardia (Phase 4)

Tachycardia, Ventricular (Phase 4)

Therapeutic Equivalency (Phase 1)

Ventricular Fibrillation (Phase 3)

Ventricular Premature Complexes (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 37
  • # of Trial Organizations: 53

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue